J Cancer 2018; 9(20):3690-3698. doi:10.7150/jca.27263 This issue
1. Department of Respiratory Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, China
2. Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210002 , China
Background: Although growing evidence have demonstrated that long non-coding RNA ZEB1-AS1 was aberrantly expressed in various types of cancers and can be used as a prognostic marker in cancer, the results remain inconclusive. Therefore, we performed this meta-analysis to evaluate the prognostic value of ZEB1-AS1 in human cancer.
Methods: A literature survey was conducted for all eligible studies by searching the following online databases: PubMed and Embase. The pooled odds ratios (ORs) or hazard ratios (HRs) with a 95 % confidence interval (95 % Cl) were computed to demonstrate its prognostic value.
Results: A total of 14 studies with 1096 individuals were included to evaluate the association of ZEB1-AS1 with clinicopathological features and overall survival (OS). In the pooled analyses stratified by clinicopathological features, ZEB1-AS1 expression was significantly related to depth of tumor (OR=2.92, 95% CI 1.22-7.02), poor histological differentiation (OR=2.72, 95% CI: 1.92-3.86), lymph node metastasis (OR=3.93, 95% CI: 2.65-5.84), distant metastasis (OR=5.34, 95% CI: 2.85-10.02) and tumor stage (OR=2.46, 95% CI 1.42-4.24), but not to tumor size (OR=1.25, 95% CI 0.79-1.96). Altered ZEB1-AS1 expression was found to be an indicator of worse prognosis in OS (HR = 1.94, 95% CI: 1. 66-2.22) among tumor patients.
Conclusions: High ZEB1-AS1expression was associated poor clinical outcome and it can serve as a novel predictive biomarker in various cancers.
Keywords: long non-coding RNA, ZEB1-AS1, prognostic biomarker, cancer